AER 1547912 is a spontaneous case, received on 03/Mar/2015 from a consumer via company representative and 
concerns a female patient of unknown age who developed progressive multifocal leukoencephalopathy, CD4 
dropped and CD8 dropped while being treated with rituximab (Rituxan).
The patient's medical history included hard of hearing and  chronic lyme in the periventricular area. The patient's 
Concomitant medications included chemotherapy, bendamustine, lamotrigine, venlafaxine, mirtazapine. No 
concurrent illness and past drugs were reported.
On an unspecified date, the patient started therapy with intravenous rituximab infusion for chronic lymphocytic 
leukaemia. She had 3 rounds of rituximab for aggressive lymphoma. On an unspecified date, her CD4 and CD8 
Print Time: 07-JUN-2016 03:01 PM If a field is blank, there is no data for that field Page 94 of 549
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information
were dropped. Her CD4 was 340 and dropped to 142 (normal range: 577 to1623) and CD4 - CD8 had dropped 
from .84 to .23 (when 1.3 low normal). On an unspecified date, she developed progressive multifocal 
leukoencephalopathy (PML) (It's unknown whether this is before starting rituximab). It was stated that, she was not 
willing to continue taking rituximab because of her low CD4 count. It was reported that, progressive multifocal 
leukoencephalopathy affects people in the that area.
At the time of report, outcome of event progressive multifocal leukoencephalopathy was not reported and event 
CD4 dropped and CD8 dropped were persisitng. There was insufficent information regarding therapy ongoing 
status of rituximab.
The reporter did not provide causality of progressive multifocal leukoencephalopathy, CD4 dropped and CD8 
dropped with rituximab.
The reporter assessed the event progressive multifocal leukoencephalopathy as medically significant.
No further information was provided.